Our Anti-Vimentin primary antibody from PhosphoSolutions is chicken polyclonal. It detects human, mouse, and rat Vimentin and is total IgY fraction. It is great for use in WB, IHC, ICC.
Immunostaining of tumors and precursor PanIN lesions from 4 week old LSL-KrasG12D; Cdkn2alox/lox; p48Cre (KIC) mice that were treated with 2G8 and/or gemcitabine, Gem. (Anti-Vimentin, cat. 2105-VIM, green; Anti-E-cadherin, red). Photo courtesy of Rolf Brekken, University of Texas Southwestern. CC-BY-4.0
Vimentin is the major protein subunit of the 10nm or intermediate filaments (IFs) found in many kinds of mesenchymal and epithelial cells as well as developing neuronal and astrocytic precursor cells in the CNS. Vimentin is thought to be critically involved in lymphocyte adhesion and transmigration (Nieminen M et al. 2006). Copolymers are frequently formed between vimentin and other IFs, such as GFAP (in many kinds of astrocytes), desmin (in muscle cells) and neurofilament proteins (in developing neurons). Antibodies to vimentin are useful in studies of stem cells and generally to reveal the filamentous cytoskeleton. Recent studies suggest that vimentin affects prostate cancer cells motility and invasiveness (Zhao et al. 2008).
Recommended that the undiluted antibody be aliquoted into smaller working volumes (10-30 uL/vial depending on usage) upon arrival and stored long term at -20° C or -80° C, while keeping a working aliquot stored at 4° C for short term. Avoid freeze/thaw cycles. Stable for at least 1 year.
Liquid
Total IgY fraction.
PBS + 10 mM NaN3.
WB: 1:1000
IHC: 1:500-1:5000
ICC: 1:500-1:10,000
Unconjugated
Specific for the ~50 kDa Vimentin protein.
Western blots performed on each lot.
For research use only. Not intended for therapeutic or diagnostic use. Use of all products is subject to our terms and conditions, which can be viewed on our website.
After date of receipt, stable for at least 1 year at -20°C.
Blue Ice
CTRCT30 antibody, Epididymis luminal protein 113 antibody, FLJ36605 antibody, HEL113 antibody, VIM antibody, VIME_HUMAN antibody, Vimentin antibody
Kirane, A., et al. 2015. Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Cancer Research, 75(18), pp.3699-3705.
Ostapoff, K. T., et al. 2014. Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. Cancer Research, 74(18), 4996-5007.
Ostapoff, K. T., et al. 2013. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Molecular Cancer Therapeutics, 12(7), pp.1190-1201.
Kirane, A., et al. 2012. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clinical Cancer Research, 18(18), pp.5031-5042
Kirane, A., et al. 2012. Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. Carcinogenesis, 33(9), 1639-46.